{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:16:50Z","timestamp":1773368210029,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s11883-014-0471-8","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T17:00:20Z","timestamp":1416589220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["When Compliance Is an Issue\u2014How to Enhance Statin Adherence and Address Adverse Effects"],"prefix":"10.1007","volume":"17","author":[{"given":"Kim","family":"Birtcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"issue":"3","key":"471_CR1","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/01.cir.0000441139.02102.80","volume":"129","author":"AS Go","year":"2014","unstructured":"Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28\u2013292.","journal-title":"Circulation"},{"key":"471_CR2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Trialists Collaboration, Baigent C, Blackwell L, Emberson J, et al. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"471_CR3","doi-asserted-by":"crossref","unstructured":"Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC\/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014; 63(25_PA) doi: 10.1016\/j.jacc.2013.11.002 .","DOI":"10.1016\/j.jacc.2013.11.002"},{"issue":"15","key":"471_CR4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","volume":"370","author":"MJ Pencina","year":"2014","unstructured":"Pencina MJ, Navar-Boggan AM, D\u2019Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"471_CR5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","volume":"288","author":"CA Jackevicius","year":"2002","unstructured":"Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462\u20137.","journal-title":"JAMA"},{"issue":"4","key":"471_CR6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","volume":"288","author":"JS Benner","year":"2002","unstructured":"Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455\u201361.","journal-title":"JAMA"},{"issue":"6","key":"471_CR7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1525-1497.2004.30516.x","volume":"19","author":"JJ Ellis","year":"2004","unstructured":"Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638\u201345.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"471_CR8","first-page":"388","volume":"14","author":"S Vinker","year":"2008","unstructured":"Vinker S, Shani M, Baevsky T, et al. Adherence with statins over 8 years in a usual care setting. Am J Manag Care. 2008;14(6):388\u201392.","journal-title":"Am J Manag Care"},{"issue":"7","key":"471_CR9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1185\/03007990802203279","volume":"24","author":"JM Foody","year":"2008","unstructured":"Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a U.S. managed care study. Curr Med Res Opin. 2008;24(7):1987\u20132000.","journal-title":"Curr Med Res Opin"},{"key":"471_CR10","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","volume":"34","author":"R Chowdhury","year":"2013","unstructured":"Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940\u20138.","journal-title":"Eur Heart J"},{"key":"471_CR11","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","volume":"44","author":"DM Mann","year":"2010","unstructured":"Mann DM, Woodward M, Muntner P, et al. Predictors of non-adherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44:1410\u201321.","journal-title":"Ann Pharmacother"},{"key":"471_CR12","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.cjca.2012.05.007","volume":"28","author":"M Lemstra","year":"2012","unstructured":"Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574\u201380.","journal-title":"Can J Cardiol"},{"key":"471_CR13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","volume":"6","author":"JD Cohen","year":"2012","unstructured":"Cohen JD, Brinton EA, Ito MK, et al. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208\u201315.","journal-title":"J Clin Lipidol"},{"issue":"10","key":"471_CR14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/phar.1305","volume":"33","author":"R Kazerooni","year":"2013","unstructured":"Kazerooni R, Watanabe JH, Bounthavong M. Association between statin adherence and cholesterol level reduction from baseline in a veteran population. Pharmacotherapy. 2013;33(10):1044\u201352.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"471_CR15","first-page":"e105","volume":"20","author":"MD Chi","year":"2014","unstructured":"Chi MD, Vansomphone SS, Liu IA, et al. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care. 2014;20(4):e105\u201312.","journal-title":"Am J Manag Care"},{"key":"471_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60761-8","volume":"371","author":"PM Kearney","year":"2008","unstructured":"Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117\u201325.","journal-title":"Lancet"},{"issue":"10","key":"471_CR17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-009-0673-0","volume":"65","author":"S Perreault","year":"2009","unstructured":"Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013\u201324.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"471_CR18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.18553\/jmcp.2014.20.7.703","volume":"20","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Zabriski S, Bertram C. Associations between statin adherence level, health care costs, and utilization. J Manag Care Pharm. 2014;20(7):703\u201313.","journal-title":"J Manag Care Pharm"},{"key":"471_CR19","unstructured":"Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Spec no.:SP11\u201319."},{"issue":"6","key":"471_CR20","first-page":"459","volume":"16","author":"RE Aubert","year":"2010","unstructured":"Aubert RE, Yao J, Xia F, et al. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16(6):459\u201366.","journal-title":"Am J Manag Care"},{"issue":"6","key":"471_CR21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2125.2006.02828.x","volume":"63","author":"MH Bouchard","year":"2007","unstructured":"Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol. 2007;63(6):698\u2013708.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"471_CR22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1524-4733.2009.00583.x","volume":"13","author":"A Dragomir","year":"2010","unstructured":"Dragomir A, C\u00f4t\u00e9 R, White M, et al. Relationship between adherence level to statins, clinical issue. Value Health. 2010;13(1):87\u201394.","journal-title":"Value Health"},{"issue":"7","key":"471_CR23","first-page":"703","volume":"20","author":"DG Pittman","year":"2014","unstructured":"Pittman DG, Chen W, Zhao Y, Zabriski S, Bertram C. Associations between statin adherence level, health care costs, and utilization. J Manag Care Pharm. 2014;20(7):703\u201313. This study demonstrates the association between better statin adherence for a 1-year period with lower healthcare costs and fewer cardiovascular disease-related hospitalizations during the subsequent 18 months. Clinicians and health benefits managers should emphasize statin adherence in the first year.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"471_CR24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.18553\/jmcp.2014.20.1.51","volume":"20","author":"JF Slejko","year":"2014","unstructured":"Slejko JF, Ho PM, Anderson HD, et al. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51\u20137. The authors demonstrated that statin adherence declines over a 3-year period even if the patient is adherent during the first year of therapy, and transition to adherence levels <80 % was associated with increased cardiovascular events. The second-year adherence level was a significant predictor of cardiovascular event hazard (p\u2009<\u20090.001). Clinicians and health benefits managers should emphasize statin adherence long-term.","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"471_CR25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","volume":"25","author":"MA Fischer","year":"2010","unstructured":"Fischer MA, Stedman MR, Lii J, et al. Primary medication nonadherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284\u201390.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"471_CR26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11606-011-1829-z","volume":"27","author":"MA Raebel","year":"2012","unstructured":"Raebel MA, Ellis JL, Carroll NM, et al. Characteristics of patients with primary nonadherence to medications for hypertension, diabetes, and lipid disorders. J Gen Intern Med. 2012;27(1):57\u201364.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"471_CR27","first-page":"111","volume":"2","author":"JN Liberman","year":"2010","unstructured":"Liberman JN, Hutchins DS, Popiel RG, et al. Determinants of primary nonadherence in asthma-controller and dyslipidemia pharmacotherapy. Am J Pharm Benefits. 2010;2(2):111\u20138.","journal-title":"Am J Pharm Benefits"},{"issue":"5","key":"471_CR28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.18553\/jmcp.2013.19.5.367","volume":"19","author":"TC Cheetham","year":"2013","unstructured":"Cheetham TC, Niu F, Green K, et al. Primary nonadherence to statin medications in a managed care organization. J Manag Care Pharm. 2013;19(5):367\u201373.","journal-title":"J Manag Care Pharm"},{"issue":"11","key":"471_CR29","doi-asserted-by":"crossref","first-page":"e79611","DOI":"10.1371\/journal.pone.0079611","volume":"8","author":"AJ Zimolzak","year":"2013","unstructured":"Zimolzak AJ, Spettell CM, Fernandes J, et al. Early detection of poor adherers to statins: applying individualized surveillance to pay for performance. PLoS ONE. 2013;8(11):e79611. Lower adherence (PDC <0.80) in the first 90 days of statin therapy was the strongest predictor for poor adherence at 1\u00a0year (OR 25.0, 95 % CI 23.7\u201326.5) in patients initiating statin therapy. Predictions could be made as early as 40 days after statin initiation for individuals who get 30-day supplies of medication and 100 days after statin initiation for individuals who get 90-day supplies of medication. Plan administrators and pharmacy benefits managers could use an individualized surveillance model similar to the one used in this study to detect early which beneficiaries will fall below the designated adherence threshold.","journal-title":"PLoS ONE"},{"key":"471_CR30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","volume":"15","author":"P Maningat","year":"2013","unstructured":"Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15:291\u20138.","journal-title":"Curr Atheroscler Rep"},{"key":"471_CR31","doi-asserted-by":"crossref","unstructured":"Romanelli RJ, Segal JB. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries. J Gen Intern Med. 2014;24.","DOI":"10.1007\/s11606-014-2933-7"},{"issue":"1","key":"471_CR32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.298.1.61","volume":"298","author":"DP Goldman","year":"2007","unstructured":"Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61\u20139.","journal-title":"JAMA"},{"key":"471_CR33","unstructured":"EaddyMT, Cook CL, O\u2019Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012;37:45\u201355."},{"issue":"11","key":"471_CR34","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1377\/hlthaff.2010.0571","volume":"29","author":"ML Maciejewski","year":"2010","unstructured":"Maciejewski ML, Farley JF, Parker J, et al. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002\u20138.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"471_CR35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hec.1245","volume":"17","author":"P Thiebaud","year":"2008","unstructured":"Thiebaud P, Patel BV, Nichol MB. The demand for statin: the effect of copay on utilization and compliance. Health Econ. 2008;17(1):83\u201397. 24.","journal-title":"Health Econ"},{"issue":"12","key":"471_CR36","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1016\/j.clinthera.2007.12.022","volume":"29","author":"X Ye","year":"2007","unstructured":"Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748\u201357.","journal-title":"Clin Ther"},{"issue":"1","key":"471_CR37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18553\/jmcp.2014.20.1.34","volume":"20","author":"S Chen","year":"2014","unstructured":"Chen S, Shah SN, Lee Y, et al. Moving branded statins to lowest copay tier improves patient adherence. J Manag Care Pharm. 2014;20(1):34\u201342.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"471_CR38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.18553\/jmcp.2014.20.1.43","volume":"20","author":"JH Watanabe","year":"2014","unstructured":"Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014;20(1):43\u201350. This study demonstrated better adherence with statins for new statin users who did not have a copayment for their statin versus patients who had a copayment for their statins. It will be important for insurance benefits managers to evaluate total healthcare costs of eliminating or reducing copayments for prescriptions medications. In the long-run, the plan may benefit from less expenditures and better clinical outcomes.","journal-title":"J Manag Care Pharm"},{"key":"471_CR39","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","volume":"365","author":"NK Choudhry","year":"2011","unstructured":"Choudhry NK, Avorn J, Glynn RJ, et al. Post-myocardial infarction free Rx event and economic evaluation (MI FREEE) trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088\u201397. This study demonstrated better adherence with statins and better clinical outcomes for new statin users who did not have a copayment for their statin versus patients who had a copayment for their statins. It will be important for insurance benefits managers to evaluate total healthcare costs of eliminating or reducing copayments for prescriptions medications. In the long-run, the plan may benefit from less expenditures and better clinical outcomes.","journal-title":"N Engl J Med"},{"key":"471_CR40","unstructured":"Visante. How copay coupons could raise prescription drug costs by $32 billion over the next decade [white paper]. Pharm Care Manag Assoc. 2011. http:\/\/www.pcmanet.org\/images\/stories\/uploads\/2011\/Nov2011\/visante%20copay% . Accessed July 15, 2014."},{"issue":"9","key":"471_CR41","doi-asserted-by":"crossref","first-page":"765","DOI":"10.18553\/jmcp.2013.19.9.765","volume":"19","author":"JB Daugherty","year":"2013","unstructured":"Daugherty JB, Maciejewski ML, Farley JF. The impact of manufacturer coupon use in the statin market. Manag Care Pharm. 2013;19(9):765\u201372.","journal-title":"Manag Care Pharm"},{"key":"471_CR42","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","volume":"158","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. Ann Intern Med. 2013;158:526\u201334. Statin rechallenging is a viable option for some patients who report statin-related side effects.","journal-title":"Ann Intern Med"},{"key":"471_CR43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","volume":"166","author":"WM Mampuya","year":"2013","unstructured":"Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597\u2013603. Statin rechallenging is a viable option for some patients who report statin-related side effects. Patients on intermittent statin dosing achieved similar LDL-C reductions to patients on daily statin dosing.","journal-title":"Am Heart J"},{"key":"471_CR44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","volume":"47","author":"AJ Keating","year":"2013","unstructured":"Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013;47:398\u2013404. The authors noted that at least 70 % of patients with prior statin-related side effects were able to tolerate intermittent statin dosing, ranging from every-other-day to once-weekly dosing, without a recurrence of previous statin-related adverse effects.","journal-title":"Ann Pharmacother"},{"key":"471_CR45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","volume":"160","author":"TR Joy","year":"2014","unstructured":"Joy TR, Monjed A, Zou GY. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med. 2014;160:301\u201310. Statin rechallenging is a viable option for some patients who report statin-related side effects. Though the investigators and patients in this study used matching statin and placebo doses, the other methodology used to discern the difference in side-effects to statin and placebo could be used in other clinical settings.","journal-title":"Ann Intern Med"},{"key":"471_CR46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735\u201342.","journal-title":"Lancet"},{"key":"471_CR47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565\u201371.","journal-title":"Lancet"},{"key":"471_CR48","unstructured":"Dixon D, Nash D, Bolick J, et al. Patient adherence tool kit. https:\/\/www.lipid.org\/practicetools\/tools\/adherence . Accessed 30 May 2014. The toolkit challenges clinicians to view adherence as a disease, which will require an understanding what represents adherence, how to \u201cdiagnose\u201d it in patients, and what evidence-based interventions have been successful at improving patient adherence."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-014-0471-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-014-0471-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-014-0471-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:21:23Z","timestamp":1747167683000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-014-0471-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s11883-014-0471-8","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]},"article-number":"471"}}